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Abstract
A tendency toward bleeding often undercuts the beneficial preventive effect of higher doses of a
single antithrombotic drug or combined antithrombotic therapy. Although high doses of
antithrombotic drugs may be necessary for optimal prevention, such therapy can also elicit more
frequent bleeding. Although major bleeding could be a reversible event is likely to lead clinicians to
discontinue antithrombotic therapy which in turn could increase the risk of myocardial infarction,
stroke, and cardiovascular death. Thus, to prevent thrombotic events without frequent bleeding
complications, the preferred approach might be to use anti-inflammatory drugs in addition to the
first-line antithrombotic drugs to reduce inflammation and thrombin formation in atheroma.
Although some preliminary data have been already published, to confirm the potential benefit of
anti-inflammatory drugs in acute coronary syndromes large prospective double-bind randomized
trials are necessary.
Background
The hemostatic system is a physiological process to pre-
vent hemorrhage and maintain a balance between clot
formation and fluidity of blood in the circulation. After
endothelial injury, platelets adhere to the exposed suben-
dothelium and are activated by locally released agonists to
stimulate thrombin formation [1], contributing to hemo-
static control. Under other circumstances, such as in arte-
rial disease, clots form upon atheroma rupture, primarily
in connection with plaque conditions and in situ
thrombin generation. After a clot starts to form, its growth
depends on platelet recruitment and aggregation, concen-
tration of thrombin at the surface of the clot, and changes
in local blood flow. Thus, clot growth can be inhibited by
blocking thrombus-bound thrombin activity and/or by
inhibiting platelet function.
Thrombin is the strongest platelet agonist, and inhibition
of thrombin can also prevent platelet activation. In fact,
any intervention singly directed at thrombin activity or
platelet activation may simultaneously affect the other
function [2].
Aspirin (acetylsalicylic acid), and clopidogrel, are the
mainstay antiplatelet therapies for arterial disease.
Together with heparin, they constitute the first-line treat-
ments for acute coronary disease. Clinical trials have
established the benefit of aspirin for coronary prevention,
and it is considered the gold standard for arterial anti-
thrombotic therapy – despite its limitations with regard to
preventing thrombosis.
Coadministration of aspirin and clopidogrel enhances
platelet inhibition, because these agents act through dif-
ferent platelet receptors; however, the benefit of com-
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bined antiplatelet treatment over aspirin alone in
preventing thrombotic outcomes is debated [3-5].
Therapies that include multiple drugs affecting primary
hemostasis (antiplatelet drugs) or a combination of
antiplatelets and anticoagulants, as in ischemic heart dis-
ease, are more aggressive than a single therapy. Combined
antithrombotic treatment confers particular risk and is
associated with a higher incidence of bleeding [6,7], espe-
cially among older patients and patients undergoing early
revascularization [8]. The combining therapy, of clopi-
dogrel and aspirin, causes more bleeding than mono-
therapy with either drug [9].
In arterial thrombosis, which mainly occurs on atheroma,
inflammation promotes atheroma rupture. Thus there is a
need for an alternative to high doses of antithrombotic
drugs and that evidence regarding the effectiveness of anti-
inflammatory agents will be discussed.
Thrombosis versus hemostasis mechanisms
Current speculation is that the pathways for hemostasis
may differ from the pathways of thrombosis, as it is pos-
sible to attenuate thrombosis without inhibiting hemos-
tasis [10,11].
Theoretically, the risk of thrombotic events may be
increased by the exposure of procoagulant tissue factor
(TF) to the circulation. The presence of TF on the outer
membrane is a prominent characteristic of plaque lesions.
Macrophages/foam cells, smooth muscle cells, and apop-
totic cells are sources of exposed TF. In patients with a dis-
rupted atheroma that contains abundant TF, there is
increased generation of surrounding thrombin. Procoagu-
lant microparticles from stimulated and apoptotic cells
may also contribute to acute thrombotic occlusion [12].
Microparticle tissue factor appears to play a dominant role
in fibrin generation and thrombus propagation but tissue
factor in blood may be encrypted so as not to cause
thrombosis in the absence of specific stimuli [13].
Thrombus formation is driven primarily by TF derived
from the vessel wall [14] and circulating TF contributes to
thrombosis, but is unlikely to play a significant role in
hemostasis [15].
Hemostasis normally occurs in minutes, and a small
amount of blood-borne TF can accumulate at the site of
injury. In contrast, thrombosis may occur over the course
of minutes or hours, and it involves large volumes of
blood flow, which permits accumulation of significant
amounts of blood-borne TF.
Decryption of platelet TF is linked to membrane phos-
phatidylserine. After undergoing the flip-flop process,
platelet membrane phosphatidylserine can cause decryp-
tion of platelet TF and may contribute to local hemostasis,
although the potential importance of this action is not
well defined [16]. Platelets activated by factor VIIa and
other agonists (arachidonic acid, collagen, and ADP) can
induce thrombin generation independent of external TF
and may be important in normal hemostasis [1].
Hemostasis is a local not progressive process because clot-
ting starts when 10–20 nmol/l of thrombin is formed; this
initial thrombin activity is important for hemostasis [17].
The local clotting mechanism is a process limited by sev-
eral factors such as the small amount of exposed TF in a
relatively small area of the vessel wall, dilution of activa-
tors in the bloodstream of non occluded vessels and it
inhibition by tissue factor pathway inhibitor (TFPI) and
other natural coagulation inhibitors, and restraint of clot
lysis by platelet plasminogen activator inhibitor, which
prevents the release of clot-bound thrombin.
In arterial thrombosis, which mainly occurs on atheroma,
inflammation promotes atheroma rupture. In atheroma,
the levels of TF, which is also expressed by monocytes and
macrophage-derived foam cells, are several-fold greater
than the levels in a wounded vessel [18]. Enhancement of
the TF/FVIIa complex leads to thrombin generation and
strong activation of platelets. Blood flow changes (stasis)
in a partially or fully occluded vessel prevent the dilution
of surrounding activated factors and clot-bound thrombin
and, together with platelet-erythrocyte interaction and
thrombin-activatable fibrinolysis inhibitor (TAFI), pro-
mote thrombus growth. Elevated levels of TAFI in coro-
nary heart disease are associated with risk of arterial
thrombosis [19]. Also, in unstable angina and silent
ischemia, local thrombolysis releases fibrin-bound
thrombin, favoring thrombus growth [20].
Dose-ranging studies of antithrombotic agents
Numerous randomized controlled trials have evaluated
the effectiveness and safety of anticoagulants or antiplate-
let therapy or different combinations of anticoagulant and
antiplatelet therapy; or dual antiplatelet therapy were
compared with aspirin in short or long-term thrombosis
prevention studies.
In a dose-ranging trial of enoxaparin 1.25 mg/kg and 1.0
mg/kg (every 12 hr) in patients with unstable angina, the
incidence of death, recurrent myocardial infarction, or
recurrent ischemia requiring revascularization was 5.6%
with the higher dose and 5.2% with the lower dose [21].
Major hemorrhage occurred in 1.9% of patients in the 1.0
mg/kg group and 6.5% in the 1.25 mg/kg group (p =
0.03). Thus, lower dose achieved equivalent risk reduc-
tion with less bleeding [21]. Similarly, in the Instability in
Coronary Artery Disease (FRISC) study where another lowThrombosis Journal 2007, 5:11 http://www.thrombosisjournal.com/content/5/1/11
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molecular weight heparin fragmin was tested, the inci-
dence of major bleeding was 6% with a dose of 150 IU/kg
every 12 hr and 0.8% with a dose of 120 IU/kg every 12 hr
[22].
Melagatran and dabigatran are active antithrombin drugs
that selectively and competitively inhibit free and clot-
bound thrombin. After oral administration, ximelagatran
is absorbed and biotransformed to melagatran, the domi-
nant compound in plasma. In a dose-ranging study com-
paring melagatran/ximelagatran to the low molecular
weight dalteparin, the highest dose of ximelagatran had
better clinical efficacy and a nonsignificant tendency
toward a greater transfusion volume in hip replacement
patients [23]. Although there were no differences in recur-
rent venous thromboembolism events during 6 months
of treatment and besides hepatotoxicity events, serious
symptomatic myocardial ischemia warranting hospitali-
zation was referred by the use of ximelagatran.
Another study reported that total bleeding (major and
minor) was lower with ximelagatran versus warfarin in
atrial fibrillation patients [24]. However, other work also
in nonvalvular atrial fibrillation patients demonstrated a
small dose-related increase in bleeding with ximelagatran
[25].
In dose-ranging studies with dabigatran, another active
antithrombin drug, in patients undergoing hip or knee
surgery [26], there was a significant dose-dependent
decrease in the frequency of venous thromboembolism
(VTE) with increasing doses of dabigatran etexilate (the
prodrug of dabigatran). The lowest rate of total VTE
(13.1%) and proximal deep venous thrombosis DVT
(1.7%) occurred in the highest dose group (225 mg twice
daily). There was also a dose-related increase in major
bleeding episodes. Hemorrhagic events were significantly
more frequent with higher doses versus the lowest dose of
dabigatran (3.8% and 0.3%, respectively). The combined
clinically significant bleeding and major hemorrhage fol-
lowed the same pattern: 8.4% with the 225 mg dose and
2.6% with the 50 mg dose. The increase in bleeding was
irrespective of the surgical procedure.
A dose-ranging study of BAY 59-7939 (Rivaroxaban), a
direct oral inhibitor of activated Factor X, was performed
with total knee replacement patients [27]. Among the five
BAY 59-7939 dose groups tested (2.5 mg, 5 mg, 10 mg, 20
mg, and 30 mg twice daily), the incidence of the primary
efficacy endpoint ranged from 23.3% (10 mg twice daily)
to 40.4% (5 mg twice daily). There was a trend toward effi-
cacy with the higher dose, although it was not significant
based on the total daily dose (p = 0.29). However, there
was a statistically significant dose-related increase in post-
operative major bleeding episodes (1.0%, 0%, 1.9%,
3.1%, and 7.5% for 2.5 mg, 5 mg, 10 mg, 20 mg, and 30
mg twice daily, respectively; p = 0.0007). Mean transfu-
sion volumes were lowest for patients receiving 2.5 mg
and highest for patients receiving 30 mg. In a second dose-
finding study of BAY 59-7939 in total hip replacement
patients [28], there was a significant dose-dependent
trend, with the highest dose yielding better efficacy than
the lowest dose. Major postoperative bleeding was signif-
icant and dose-related (0.8%, 2.2%, 2.3%, 4.5%, and
5.4% for 2.5 mg, 5 mg, 10 mg, 20 mg, and 30 mg BAY 59-
7939 twice daily, respectively).
A third dose-ranging study with BAY 59-7939 adminis-
tered as a single daily dose was recently published [29].
Results in total hip replacement patients were generally
similar to those obtained in the previous studies.
Although there was a flat dose-response relationship for
the primary efficacy endpoint (p = 0.0852), there was a
significant dose-response relationship for major venous
thromboembolism (p = 0.0072). Nevertheless, a single
oral dose of 30 mg was less effective than a single oral
dose of 20 mg and increased the frequency of postopera-
tive major bleeding events. In all groups receiving BAY 59-
7939, major postoperative bleeding occurred upon the
first postoperative dose and was significant (p = 0.0391)
and dose related.
Taken together, the results of dose-finding studies of BAY
59-7939 lead to an interesting observation: it appears that
higher doses increase the frequency of major postopera-
tive bleeding events and are less effective in preventing
venous thromboembolism compared to moderate doses.
This could be by chance or because the anti-thrombotic
effect is related to the strongest in situ inhibition of
thrombin generated in the damaged vessel wall, which
prevents local activation of protein C/thrombomodulin.
The protein C anticoagulant pathway is a major system for
controlling thrombosis and inflammation [30].
Thrombin binds to thrombomodulin and then activates
protein C approximately 1000 times faster than free
thrombin. Activated protein C proteolytically inactivates
clotting factor Va and factor VIIIa, thereby blocking the
amplification of the coagulation system [31].
Although thrombin increases protein C activation by
binding to endothelial thrombomodulin, in atheroma,
inflammation might overwhelm protective anticoagulant
forces [32]. Inadequate amounts of residual thrombin due
to therapy might prevent protein C from local activation,
preventing the inactivation of factor Va and factor VIIIa by
protein C. This in turn would allow activated factors V and
factor VIII further activation of the clotting pathways with
a local thrombus growing in one or more coronary, cere-
brovascular, or peripheral artery atheroma. Thus, we canThrombosis Journal 2007, 5:11 http://www.thrombosisjournal.com/content/5/1/11
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speculate that strong inhibition of local thrombin could
paradoxically enhancing local thrombus formation
instead of prevention.
The hypothesis that strong inhibition of thrombin could
causes adverse outcomes is consistent with the physiolog-
ical importance of activated protein C in the protein C
anticoagulant pathway and in the control of the innate
inflammatory response and because clinical studies reveal
that deficiencies of protein C lead to microvascular
thrombosis [30,33].
During treatment with antithrombotic drugs, in the pres-
ence of a wounded vessel, the relatively small amount of
thrombin generated in situ is also inhibited by therapy.
This can affect hemostasis with the potential consequence
of bleeding and, although major bleeding could be a
reversible event, antithrombotic therapy must be stopped
which in turn could increase the risk of arterial thrombo-
sis and death [34].
Platelets also play a central role in initiating and propagat-
ing pathological thrombosis.
Antiplatelet therapy is important in the management of
acute coronary syndromes after spontaneous plaque dis-
ruption or mechanical disruption caused by percutaneous
coronary intervention. Aspirin is the gold standard for
prevention of acute myocardial syndromes, but higher
dosages of aspirin do not provide better protection from
events and are associated with increased risks of gastroin-
testinal bleeding [35].
The CURE trial [36] investigated the benefit of combined
antiplatelet treatment (aspirin-clopidogrel) over aspirin
alone in preventing thrombotic outcomes in patients with
acute coronary syndrome. Major bleeding was signifi-
cantly more common in the clopidogrel plus aspirin
group (3.7%) versus the aspirin group (2.7%, p = 0.001).
The sub-study of the CURE trial [37] showed that bleeding
risks increase with increasing aspirin dose, without any
increase in efficacy, and further increase with addition of
clopidogrel to different doses of aspirin (Table 1). The
CREDO trial evaluated the benefit of long-term treatment
with clopidogrel in addition to aspirin therapy in patients
after percutaneous coronary intervention. At 1 year there
was an absolute reduction of 3% in the combined risk of
death, MI, or stroke in favor of clopidogrel plus aspirin
versus placebo plus aspirin. There was also a clear but
nonsignificant difference in the risk of major bleeding
(8.8% with clopidogrel-aspirin vs. 6.7% with placebo-
aspirin; p = .07; absolute increase of 2.1%) [38]. The Cha-
risma [3] study investigated, in patients with clinically evi-
dent cardiovascular disease or multiple risk factors, the
benefit to receive clopidogrel (75 mg per day) plus low-
dose aspirin (75 to 162 mg per day) or placebo plus low-
dose aspirin. The use of clopidogrel-aspirin did not fur-
ther reduce the incidence of the primary end point (myo-
cardial infarction, stroke, or death from cardiovascular
causes) compared to aspirin alone. However, considering
the GUSTO definition, clopidogrel was associated with a
significant increase in the rate of moderate bleeding or
moderate and severe bleeding (Table 2). Although severe
bleeding alone was not significantly greater with clopi-
dogrel, a trend of concern was noted.
The JUMBO-TIMI 26 trial [39] investigated a new
antiplatelet drug, the thienopyridine P2Y12 ADP receptor
antagonist prasugrel, in patients undergoing elective or
urgent percutaneous coronary intervention. Patients were
treated with a low dose (40 mg loading dose followed by
7.5 mg daily), an intermediate dose (60 mg loading dose
followed by 10 mg daily), or a high dose (60 mg loading
dose followed by 15 mg daily) of prasugrel or clopidogrel.
Among prasugrel-treated patients, there were no group
differences in the frequency of major adverse coronary
events, although at 30 days myocardial infarction was less
frequent in the high-dose group. At 30 days there was a
trend toward a higher incidence of the composite of
major, minor, or minimal bleeding for the high-dose
prasugrel group (5.1%) compared to the intermediate and
low-dose groups (3.5% with each). As expected, the vascu-
lar access site was the most frequent site of bleeding [39].
The JUMBO trial findings suggest that prasugrel is more
potent than clopidogrel, but two episodes of profound
platelet inhibition with prasugrel raise the possibility of a
higher bleeding risk [40].
The reviewed studies suggest that when comparing low
and high doses of antithrombotic drugs there is a strong
dose-relationship regarding the capacity to prevent arte-
Table 1: Major bleeding with aspirin versus bleeding with 
clopidogrel plus aspirin.
Aspirin daily dose Major bleeding NNH 
Single/
dual 
therapy
Aspirin Aspirin+ 
clopidogrel
≤100 mg (%) 1.86 2.97 54/34
101–199 mg (%) 2.82 3.41 35/29
≥200 mg (%) 3.67 4.86 27/21
p = <0.0001 < 0.001
Major bleeding with aspirin versus bleeding with clopidogrel plus 
aspirin. Shown by NNH, bleeding risks increase with increasing aspirin 
dose and further increase with addition of clopidogrel to different 
doses of aspirin (Data from sub-study of the CURE trial [37]).
NNH: Number Needed to HarmThrombosis Journal 2007, 5:11 http://www.thrombosisjournal.com/content/5/1/11
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rial thrombosis, but there is only a weak dose-relationship
when comparing intermediate and high doses. However,
there was a clear dose-related effect on bleeding risk in all
trials. Thus, the highest doses of antithrombotic drugs
yield the most frequent bleeding without providing the
greatest level of prevention.
A possible alternative to current antithrombotic therapy
At present, there is agreement that vessel wall inflamma-
tion is a major factor in the development of atherosclero-
sis, atheroma instability, and plaque disruption, events
that are followed by local thrombosis, which underlies the
clinical presentation of acute coronary syndromes.
Inflammation is a reflexive response to mechanical irrita-
tion, or injury, and although restricted inflammation is
beneficial, persistent inflammation incites tissue destruc-
tion [41]. In healthy subjects, the mean level of TF antigen
in plasma is in the range of 149–172 pg/ml, whereas the
levels of blood-borne TF are increased in atherosclerosis
[42]. Plaque in unstable angina possesses elevated levels
of TF that could be released during inflammation, increas-
ing local thrombin generation and precipitating acute
clinical syndromes. TF expressed by foam cells and in the
necrotic core of plaque are higher in atheroma from
patients with unstable angina compared with patients
with stable angina [43]. Therefore, inflammation releas-
ing TF, plays a pivotal role in the initiation of thrombotic
complications in patients with coronary artery disease
[44] (Figure 1).
In agreement with this, there is evidence that blocking
inflammation can prevent thrombosis and acute coronary
events. For example Versaci et al. [45] reported that corti-
costeroids have the potential to reduce the inflammatory
response associated with stent implantation in patients
with high C-reactive protein levels. The 12-month event-
free survival rate was 93% and 65% in patients treated
with prednisone and placebo, respectively. The 6-month
restenosis rate was significantly lower for patients treated
with prednisone versus those treated with placebo (7% vs.
33%, p = 0.001). Thus, prednisone reduces clinical events
and the rate of angiographic restenosis.
Glucocorticoids can have rapid effects on inflammation
but prolonged or high-dose glucocorticoid therapy has
multiple side effects [46].
Altman et al.[47] (Table 3) reported findings from a pilot
study showing that treatment with meloxicam, a preferen-
tial COX-2 inhibitor, is associated with a significant
reduction in recurrent angina, non-fatal infarction, and
cardiac death in patients with acute coronary syndromes
Table 3: Results of the NUT study.
Events (%) at 3-month Follow-up RR 
(%)
AR 
(%)
NN
T
Patients (n) 60 60
Recurrent angina + MI 58.6 28.3 3.5
Revascularization (PTCA and CABG) 61.0 18.3 5.5
Recurrent angina + MI + mortality 55.2 26.3 3.8
MI + revascularization + mortality 60.1 20 5.0
Results of the NUT study [34].
RR: Relative Reduction, AR: Absolute Reduction
NNT: Number Needed to Treat, MI: Myocardial Infarction.
Table 2: Comparison of ischemic risk prevention and bleeding with clopidogrel plus aspirin (clop + ASA) versus aspirin plus placebo 
(ASA + placebo).
Ischemic Events Bleeding Events
Trial
(observation 
period)
clop + ASA 
(%)
ASA + 
placebo (%)
p NNT clop + ASA
(%)
ASA + 
placebo
(%)
pN N H
Cure [36]
(1 year)
9.3 11.4 <0.001 47.6 major 3.7
minor 5.1
total 8.5
major 2.7
minor 2.4
total 5.0
<0.001
<0.001
<0.001
100
37
28.6
Credo [38]
(1 years)
8.5 11.2 0.02 37.0 severe 8.8
minor 5.3
severe 6.7
minor 5.6
0.07
0.92
250
Charisma [3]
(2.5 years)
6.8 7.3 0.22 200 severe 1.7
moderate 2.1
moderate + 
severe 3.8
severe1.3
moderate 1.3
moderate + 
severe 2.6
0.09
<0.001
<0.001
250
125
83.3
Comparison of ischemic risk prevention and bleeding with clopidogrel plus aspirin (clop + ASA) versus aspirin plus placebo (ASA + placebo). 
Aspirin plus clopidogrel increased the incidence of bleeding events compared with aspirin plus placebo. Comparing the primary endpoint reduction 
with the two treatments, it appears that increased frequency of bleeding can limit the benefits of combined therapy.
NNT: Number Needed to Treat
NNH: Number Needed to HarmThrombosis Journal 2007, 5:11 http://www.thrombosisjournal.com/content/5/1/11
Page 6 of 9
(page number not for citation purposes)
without ST-segment elevation both in the care unit and
after 3 months of follow-up. No adverse complications
associated with meloxicam treatment were detected dur-
ing the observation period.
There is accumulating evidence that the lipid-independ-
ent effects of cholesterol-lowering drugs are also relevant
to the management of acute coronary syndromes. Statins
exert a number of pleiotropic effects, including improve-
ment of endothelial function, stabilization of atheroscle-
rotic plaques, and inhibition of inflammatory responses.
The anti-inflammatory effects of statins may have a clini-
cal impact on vascular and nonvascular conditions such
as multiple sclerosis and rheumatoid arthritis [48-50].
Pretreatment with atorvastatin 40 mg/day for 7 days sig-
nificantly reduced procedural myocardial injury in
patients undergoing elective coronary intervention [51].
In the ARMYDA-ACS trial, pretreatment of patients with
non-ST-segment-elevation acute coronary syndrome with
atorvastatin 80 mg 12 hr before percutaneous coronary
intervention resulted in an 88% reduction in the relative
risk of MACE at 30 days [52].
Atherothrombotic complications develop as a result of
atherosclerosis in one or more coronary, cerebrovascular,
or peripheral arteries. Is the thrombin generated in a dis-
rupted atheroma similar in all patients? In the same
patient is the thrombin generated in an inflamed plaque
and a culprit lesion similar? Why are diabetic patients
more resistant to the effects of antiplatelet drugs than are
nondiabetic patients? [53].
Based on the differences in the mechanisms underlying
hemostasis and thrombosis, a practical point can be made
regarding antithrombotic therapies. Although increased
concentrations of antithrombotic drugs will affect both
thrombosis and hemostasis, because thrombin generated
in hemostasis is lower than in thrombosis, any increase in
anticoagulant potential will produce a tendency toward
bleeding [54]. Therefore, searching for alternative thera-
pies in arterial thrombotic events suppressing inflamma-
tion with anti-inflammatory drugs could reduce thrombin
formation in the disrupted atheroma lowering the need,
of antithrombins or antiplatelet drugs (Figure 2).
However, in 2001, Mukherjee et al. [55] recommended
caution in prescribing selective COX-2 inhibitors due to
evidence for an increased risk of cardiovascular. The prob-
able explanation for this finding is that selective inhibi-
tion of COX-2 reduces endothelial production of
prostacyclin without affecting platelet production of
TXA2, producing an imbalance in hemostatic prostanoids
that might increase the risk for thrombotic cardiovascular
events [56,57]. Reducing platelet production of TXA2 by
the concomitant use of aspirin might offset the prothrom-
botic effect of selective COX-2 inhibitor. and other
NSAID-related MI risk.
As mentioned above, preliminary data from our rand-
omized controlled trial of the preferential COX-2 inhibi-
tor meloxicam in patients with acute coronary syndrome
who were treated with aspirin demonstrated a statistically
significant reduction in cardiovascular events [42] and no
clinical complications during the study period. Also, anal-
yses have established that C-reactive protein, a marker of
inflammatory activation, is a significant predictor of
adverse cardiovascular events in patients with atheroscle-
rosis, independent of baseline characteristics and treat-
ments [58]. It was showed that coadministration of the
selective COX-2 inhibitor rofecoxib with low-dose aspirin
decreases inflammatory and oxidative indices, attenuating
C-reactive protein and interleukin-6 [59,60].
Very recently Koo et al. present the report on the use of the
COX-2 inhibitor celecoxib, to reduce restenosis of patients
underwent coronary angioplasty. After 6 months paclit-
axel-eluting stent implantation mean in-stent late luminal
loss was lower in the celecoxib group (0.49 mm, SD 0.47)
than in the control group (0.75 mm, SD 0.60, absolute
difference 0.26 mm; 95% CI 0.12–0.40). Also celecoxib
reduced the need for revascularisation of the target lesion
[61].
Thrombin generation in a disrupted atheroma Figure 1
Thrombin generation in a disrupted atheroma. After plaque 
rupture, local inflammation leads to exposure of TF to the 
surrounding blood, initiating thrombin generation. Activated 
platelets release active components from the cytosol, which 
induces the externalization of phosphatidylserine through the 
flip-flop mechanism. Platelets exerts a regulatory function by 
serving as a source of inflammatory mediators and interacting 
with circulating white cells. Local blood flow changes in the 
culprit artery increase in situ prothrombotic conditions. 
Local fibrinolysis release thrombin-bound fibrin and contrib-
ute to thrombus growth.
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In conclusion, the beneficial preventive effect of high
doses of a single antithrombotic drug or combined anti-
thrombotic therapy could be overcome by the tendency
toward bleeding. and there is a dose-related association
between bleeding and death [62]. Determining the appro-
priate balance between preventing ischemic events and
causing bleeding in these patients presents a challenging
problem for clinicians [62], because in everyday clinical
practice, patients may be at greater risk of major bleeding
and ischemic events.
Thus, the preferred approach might be to use anti-inflam-
matory drugs in addition to antithrombin drugs and aspi-
rin to reduce inflammation and thrombin formation in
atheroma. Although some preliminary data have been
already published, in acute coronary syndromes large pro-
spective double-bind randomized trials are necessary to
confirm the potential benefit of this treatment.
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